Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer

Autor: Stenehjem DD, Yoo M, Unni SK, Singhal M, Bauer H, Saverno K, Quah C, Masaquel A, Brixner DI

Publikováno v: Breast Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 169-177 (2014)

David D Stenehjem,1,2 Minkyoung Yoo,1 Sudhir K Unni,1 Mukul Singhal,1 Hillevi Bauer,1 Kim Saverno,1 Cheng Quah,3 Anthony Masaquel,3 Diana I Brixner1,41Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake

Externí odkaz: https://doaj.org/article/d20a95d5003542918f52ce0ae9052846

Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty.

Autor: Murugappan MN; ORISE Fellow, Office of Oncologic Diseases, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA; Department of Pharmaceutical Care and Health Systems, University of Minnesota - College of Pharmacy, Minneapolis, MN, USA. Electronic address: Meena.Murugappan@fda.hhs.gov., King-Kallimanis BL; LUNGevity Foundation, Chicago, IL, USA., Bhatnagar V; Oncology Center for Excellence U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA., Kanapuru B; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA., Farley JF; Department of Pharmaceutical Care and Health Systems, University of Minnesota - College of Pharmacy, Minneapolis, MN, USA., Seifert RD; Department of Pharmaceutical Care and Health Systems, University of Minnesota - College of Pharmacy, Minneapolis, MN, USA., Stenehjem DD; Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota - College of Pharmacy, Minneapolis, MN, USA., Chen TY; ORISE Fellow, Office of Oncologic Diseases, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA., Horodniceanu EG; Oncology Center for Excellence U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA., Kluetz PG; Oncology Center for Excellence U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA.

Publikováno v: Journal of geriatric oncology [J Geriatr Oncol] 2024 Mar; Vol. 15 (2), pp. 101681. Date of Electronic Publication: 2023 Dec 16.

Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma.

Autor: Murugappan MN; Office of Oncologic Diseases, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA. Meena.Murugappan@fda.hhs.gov.; Department of Pharmaceutical Care and Health Systems, University of Minnesota - College of Pharmacy, Minneapolis, MN, USA. Meena.Murugappan@fda.hhs.gov.; Oncology Center of Excellence, Food and Drug Administration, Building 22, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. Meena.Murugappan@fda.hhs.gov., King-Kallimanis BL; LUNGevity Foundation, Chicago, IL, USA., Bhatnagar V; Oncology Center for Excellence (U.S. FDA), Silver Spring, MD, USA., Kanapuru B; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA., Farley JF; Department of Pharmaceutical Care and Health Systems, University of Minnesota - College of Pharmacy, Minneapolis, MN, USA., Seifert RD; Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota - College of Pharmacy, Minneapolis, MN, USA., Stenehjem DD; Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota - College of Pharmacy, Minneapolis, MN, USA., Chen TY; Office of Oncologic Diseases, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (U.S. FDA), Silver Spring, MD, USA., Horodniceanu EG; Oncology Center for Excellence (U.S. FDA), Silver Spring, MD, USA., Kluetz PG; Oncology Center for Excellence (U.S. FDA), Silver Spring, MD, USA.

Publikováno v: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2023 Aug; Vol. 32 (8), pp. 2281-2292. Date of Electronic Publication: 2023 Mar 20.

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.

Autor: Pokorny R; Department of Pharmacy, 20270Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Stenehjem DD; Department of Pharmacy Practice and Pharmaceutical Sciences, 14713University of Minnesota, College of Pharmacy, Duluth, MN, USA., Gilreath JA; Department of Pharmacotherapy, College of Pharmacy and 20270Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2022 Jun; Vol. 28 (4), pp. 916-923. Date of Electronic Publication: 2022 Feb 08.

BRCA testing and outcomes in women with breast cancer.

Autor: Stenehjem DD; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. stene032@d.umn.edu.; Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, 1110 Kirby Drive, 232 Life Science, Duluth, MN, 55812, USA. stene032@d.umn.edu., Telford C; AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.; GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC, 27709, USA., Unni SK; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.; Daiichi-Sankyo, Basking Ridge, NJ, USA., Bauer H; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA., Sainski A; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.; Truven Health, Ann Arbor, MN, USA., Deka R; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.; University of Southern California, San Diego, CA, USA., Schauerhamer MB; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA., Ye X; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA., Tak CR; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.; Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Ma J; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.; Amgen Inc, Thousand Oaks, CA, 91320, USA., Dalvi TB; AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA., Gutierrez L; RTI Health Solutions, Barcelona, Spain., Kaye JA; RTI Health Solutions, Waltham, MA, USA., Tyczynski JE; AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.; AbbVie Inc, Pharmacovigilance and Patient Safety, North Chicago, IL, USA., Brixner DI; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA., Biskupiak JE; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Apr; Vol. 186 (3), pp. 839-850. Date of Electronic Publication: 2021 Jan 03.